Dx Deal Review Q2 2024
Leveraging Non-Invasive Testing in CNS and Transplant Rejection: Ongoing Research and Early Pharma Partnerships Drive Diagnostic Innovations.
Dx Deal Review Q2 2024
Download Request
Dx Deal Review Q1 2024
With deal volumes holding steady compared to Q1 2023 we may be seeing a bottoming out of a
general decline. Companies utilising AI, oncology and CNS are all still areas of significant activity.
Dx Deal Review Q1 2024
Download Request
Dx Deal Review Q2 2023
Diagnostics (Dx) is a key component in the healthcare sector, especially within oncology where the increasing need for personalised medicine and companion diagnostics is driving dealmaking.
Dx Deal Review Q2 2023
Download Request
Dx Deal Review Q3 2023
With recent approvals of expensive personalised and targeted therapies the pressure to make these available to patients where the impact will be most effective is increasing. Diagnostics have a key role to play and this quarter we notice an increase in diagnostics deals in the CNS disease area where there is huge unmet medical need.
Dx Deal Review Q3 2023
Download Request
Dx Deal Review 2023
In 2023, the diagnostics sector saw over 430 Dx-related transactions, averaging approximately 110 deals per quarter. USA and North America generally dominated the deal space, with 68% of sellers and 61% of buyers. European engagement was lower, with 24% and 30% respectively.
Dx Deal Review 2023
Download Request
Pharma Services Overview
Despite concerns around the global political and economic landscape, the biopharmaceutical industry still maintains a favourable mid-to long-term outlook with a promising future for revenues.
The industry’s clinical pipeline remains robust, with a growing number of new molecular entities in development. Increasing complexity of molecules entering the clinical pipeline drives demand for experienced partners who can support clients, reduce investment risk and accelerate time to market.
For an overview of the key trends, current state of the market and the future outlook for CRO, CDMO, Packaging and Distribution service sectors, read PharmaVentures’ new report, Pharma Services Overview.
Pharma Services Overview
Download Request